Baricitinib for the treatment of rheumatoid arthritis

Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Urits, Jacob Israel, Hayk Hakobyan, George Yusin, Grace Lassiter, Nathan Fackler, Amnon A. Berger, Hisham Kassem, Alan Kaye, Omar Viswanath
Formato:	article
Lenguaje:	EN
Publicado:	Termedia Publishing House 2020
Materias:	rheumatoid arthritis novel treatment baricitinib janus kinase/signaling transducer and activator of transcription kinase inhibitor. Medicine R
Acceso en línea:	https://doaj.org/article/efa1b6f0f94641f0bc847beee18fbe9b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:efa1b6f0f94641f0bc847beee18fbe9b
record_format	dspace
spelling	oai:doaj.org-article:efa1b6f0f94641f0bc847beee18fbe9b2021-12-02T17:18:53ZBaricitinib for the treatment of rheumatoid arthritis0034-62332084-983410.5114/reum.2020.102006https://doaj.org/article/efa1b6f0f94641f0bc847beee18fbe9b2020-12-01T00:00:00Zhttps://www.termedia.pl/Baricitinib-for-the-treatment-of-rheumatoid-arthritis,18,42775,1,1.htmlhttps://doaj.org/toc/0034-6233https://doaj.org/toc/2084-9834Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA. This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.Ivan UritsJacob IsraelHayk HakobyanGeorge YusinGrace LassiterNathan FacklerAmnon A. BergerHisham KassemAlan KayeOmar ViswanathTermedia Publishing Housearticlerheumatoid arthritis novel treatment baricitinib janus kinase/signaling transducer and activator of transcription kinase inhibitor.MedicineRENRheumatology, Vol 58, Iss 6, Pp 407-415 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis novel treatment baricitinib janus kinase/signaling transducer and activator of transcription kinase inhibitor. Medicine R
spellingShingle	rheumatoid arthritis novel treatment baricitinib janus kinase/signaling transducer and activator of transcription kinase inhibitor. Medicine R Ivan Urits Jacob Israel Hayk Hakobyan George Yusin Grace Lassiter Nathan Fackler Amnon A. Berger Hisham Kassem Alan Kaye Omar Viswanath Baricitinib for the treatment of rheumatoid arthritis
description	Rheumatoid arthritis (RA) is a common inflammatory disease with several implications on health, disability and economy. Conventional treatment for RA centers on anti-inflammatory drugs and specific targeting of tumor necrosis factor  (TNF-) and interleukin 6 (IL-6). Baricitinib is a novel, Food and Drug Administration (FDA) approved, once daily oral drug that is effective in combination with current treatment and results in significantly reduced symptoms with good safety profile. Further studies are required to find rare side effects and evaluate the long term efficacy in disease modulation and patient symptom reduction. This is a comprehensive review of the literature on baricitinib for the treatment of RA. This review provides an update on the pathophysiology, diagnosis and conventional treatment of RA, then proceeds to introduce baricitinib and the data that exists to support or refute its use in RA. The presented study also indicated clinical trials confirming the effectiveness of baricitinib in this indication.
format	article
author	Ivan Urits Jacob Israel Hayk Hakobyan George Yusin Grace Lassiter Nathan Fackler Amnon A. Berger Hisham Kassem Alan Kaye Omar Viswanath
author_facet	Ivan Urits Jacob Israel Hayk Hakobyan George Yusin Grace Lassiter Nathan Fackler Amnon A. Berger Hisham Kassem Alan Kaye Omar Viswanath
author_sort	Ivan Urits
title	Baricitinib for the treatment of rheumatoid arthritis
title_short	Baricitinib for the treatment of rheumatoid arthritis
title_full	Baricitinib for the treatment of rheumatoid arthritis
title_fullStr	Baricitinib for the treatment of rheumatoid arthritis
title_full_unstemmed	Baricitinib for the treatment of rheumatoid arthritis
title_sort	baricitinib for the treatment of rheumatoid arthritis
publisher	Termedia Publishing House
publishDate	2020
url	https://doaj.org/article/efa1b6f0f94641f0bc847beee18fbe9b
work_keys_str_mv	AT ivanurits baricitinibforthetreatmentofrheumatoidarthritis AT jacobisrael baricitinibforthetreatmentofrheumatoidarthritis AT haykhakobyan baricitinibforthetreatmentofrheumatoidarthritis AT georgeyusin baricitinibforthetreatmentofrheumatoidarthritis AT gracelassiter baricitinibforthetreatmentofrheumatoidarthritis AT nathanfackler baricitinibforthetreatmentofrheumatoidarthritis AT amnonaberger baricitinibforthetreatmentofrheumatoidarthritis AT hishamkassem baricitinibforthetreatmentofrheumatoidarthritis AT alankaye baricitinibforthetreatmentofrheumatoidarthritis AT omarviswanath baricitinibforthetreatmentofrheumatoidarthritis
_version_	1718381118479138816

Baricitinib for the treatment of rheumatoid arthritis

Ejemplares similares